Evidence map›Paper›PMID 27057831›Full record

ArticleMedicine2016

Attribution to Heterogeneous Risk Factors for Breast Cancer Subtypes Based on Hormone Receptor and Human Epidermal Growth Factor 2 Receptor Expression in Korea.

Boyoung Park, Ji-Yeob Choi, Ho Kyung Sung, Choonghyun Ahn, Yunji Hwang, Jieun Jang, Juyeon Lee, Heewon Kim, Hai-Rim Shin, Sohee Park and 5 more

Abstract readMulticenter Study
In one paragraph

Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Epidemiology of Basal-like and Luminal Breast Cancers among Black Women in the AMBER Consortium.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Boyoung ParkFrom the Graduate School of Cancer Science and Policy, National Cancer Center (BP); Department of Preventive Medicine, Seoul National University College of Medicine (J-YC, HKS, CA, YH, JJ, JL, HK, K-YY, DK, SKP); Cancer Research Center (J-YC, CA, YH, JJ, JL, HK, DK, SKP); Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Republic of Korea (J-YC, HKS, CA, YH, JJ, JL, HK, DK, SKP); Western Pacific Regional Office, World Health Organization, Manila, Philippines (H-RS); Department of Epidemiology and Health Promotion, Graduate School of Public Health, Yonsei University (SP); and Department of Surgery, Seoul National University Hospital and College of Medicine (WH-D-YN), Seoul, Korea.
Ji-Yeob Choi
Ho Kyung Sung
Choonghyun Ahn
Yunji Hwang
Jieun Jang
Juyeon Lee
Heewon Kim
Hai-Rim Shin
Sohee Park
Wonshik Han
Dong-Young Noh
Keun-Young Yoo
Daehee Kang
Sue K Park

Funding

World Health Organization 001
6 · The paper itself

Abstract

We conducted a heterogeneous risk assessment of breast cancer based on the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) calculating the risks and population-based attributable fractions (PAFs) for modifiable and nonmodifiable factors.Using matched case-control study design from the Seoul Breast Cancer Study and the national prevalence of exposure, the risks and PAFs for modifiable and nonmodifiable factors were estimated for total breast cancers and subtypes.The attribution to modifiable factors was different for each subtype (luminal A, PAF = 61.4% [95% confidence interval, CI = 54.3%-69.8%]; luminal B, 21.4% [95% CI = 18.6-24.9%]; HER2-overexpression, 59.4% [95% CI = 47.8%-74.3%], and triple negative tumors [TNs], 27.1% [95% CI = 22.9%-32.4%)], and the attribution to the modifiable factors for the luminal A and HER2-overexpression subtypes was higher than that of the luminal B and TN subtypes (P heterogeneity  ≤  0.001). The contribution of modifiable reproductive factors to luminal A type in premenopausal women was higher than that of the other subtypes (18.2% for luminal A; 3.1%, 8.1%, and -3.1% for luminal B, HER2-overexpression, and TN subtypes, respectively; P heterogeneity  ≤  0.001). Physical activity had the highest impact preventing 32.6% of luminal A, 14.5% of luminal B, 38.0% of HER2-overexpression, and 26.9% of TN subtypes (P heterogeneity = 0.014). Total reproductive factors were also heterogeneously attributed to each breast cancer subtype (luminal A, 65.4%; luminal B, 24.1%; HER2-overexpression, 57.9%, and TN subtypes, -3.1%; P heterogeneity  ≤  0.001).Each pathological subtype of breast cancer by HRs and HER2 status may be associated with heterogeneous risk factors and their attributable risk, suggesting a different etiology. The luminal B and TN subtypes seemed to be less preventable despite intervention for alleged risk factors, even though physical activity had a high preventable potential against breast cancer.

Indexed as

Breast NeoplasmsCase-Control StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedOdds RatioReceptors, EstrogenReceptors, ProgesteroneRepublic of KoreaRisk AssessmentRisk FactorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID27057831
PMCPMC4998747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.